Yahoo · Sep 30, 2026
Boston Scientific's MedSurg Diversification Bolsters Growth Prospects
BSX's MedSurg segment supports growth, with Endoscopy and Neuromodulation gains offsetting Urology challenges and portfolio gaps.
NYSE · TFX
Teleflex Incorporated
Healthcare · Medical - Instruments & Supplies
$125.12
Up+$0.93 (+0.75%)
Updated Oct 10, 2026, 9:02 PM
SID Score
5.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 5.63B
- P/E ratio
- -17.18
- Dividend yield
- 1.09%
- 52-week range
- $100.18 – $145.00
- Volume
- 424.66K
- Avg. volume
- 634.31K
Price performance · TFX
TFX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
TFX closed at $125.12 after 21 trading sessions, down 4.48% for the selected period.
- Last close
- $125.12
- Period change
- -4.48%
- Period low
- $120.09
- Period high
- $130.99
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $124.84 | $126.01 | $123.56 | $125.12 | 424.66K |
| Oct 8, 2026 | $124.02 | $124.95 | $122.0621 | $124.19 | 1M |
| Oct 7, 2026 | $125.07 | $126.84 | $122.84 | $124.48 | 928.3K |
| Oct 6, 2026 | $125.60 | $126.94 | $123.81 | $124.74 | 683.34K |
| Oct 5, 2026 | $124.52 | $127.435 | $123.23 | $125.24 | 561.64K |
| Oct 2, 2026 | $127.12 | $127.12 | $124.01 | $124.12 | 646.99K |
| Oct 1, 2026 | $125.06 | $126.5303 | $124.245 | $126.11 | 719.19K |
| Sep 30, 2026 | $126.08 | $127.06 | $124.365 | $125.04 | 644.72K |
| Sep 29, 2026 | $127.07 | $127.695 | $124.01 | $126.32 | 982.58K |
| Sep 28, 2026 | $124.26 | $128.62 | $123.515 | $127.38 | 1.58M |
| Sep 25, 2026 | $120.47 | $123.05 | $118.31 | $122.07 | 865.59K |
| Sep 24, 2026 | $122.34 | $123.14 | $119.86 | $120.09 | 869.65K |
| Sep 23, 2026 | $124.71 | $125.16 | $121.115 | $121.75 | 832.63K |
| Sep 22, 2026 | $126.35 | $127.065 | $124.16 | $124.90 | 777.14K |
| Sep 21, 2026 | $124.84 | $126.23 | $123.095 | $124.80 | 815.18K |
| Sep 18, 2026 | $125.03 | $125.83 | $124.01 | $124.52 | 1.8M |
| Sep 17, 2026 | $126.95 | $128.88 | $125.05 | $125.59 | 867.13K |
| Sep 16, 2026 | $129.13 | $130.15 | $127.72 | $128.00 | 830.22K |
| Sep 15, 2026 | $130.40 | $130.40 | $126.18 | $129.02 | 803.75K |
| Sep 14, 2026 | $132.68 | $134.27 | $129.51 | $130.30 | 976.92K |
| Sep 11, 2026 | $133.23 | $134.09 | $128.98 | $130.99 | 572.75K |
Latest TFX news
The latest Smart Investors Daily articles mentioning TFX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TFX research
Overview
Company profile and research snapshot.
Company profile
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $129.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 28, 2026 | B of A Securities | Buy | — |
| Aug 25, 2026 | Needham | Buy | — |
| Aug 11, 2026 | UBS | Neutral | — |
| Aug 10, 2026 | Truist Securities | Hold | — |
| Aug 7, 2026 | Piper Sandler | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 29, 2026
Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex
Check out the companies making headlines yesterday:
Yahoo · Sep 29, 2026
Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
WAYNE, Pa., September 29, 2026--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters during a
Yahoo · Sep 29, 2026
Should New Leadership And Debt Focus At Teleflex (TFX) Require Action From Investors?
Recently, Teleflex attracted attention as investors reacted to commentary that, despite weak constant-currency revenue growth and declining earnings metrics, some see the company as lagging broader market performance while others highlight its potential. What stands out is that new leadership and an emphasis on reducing debt are being framed as possible catalysts for a meaningful re-rating story in the eyes of investment firms. Next, we’ll examine how Teleflex’s new leadership focus and...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
